Bukwang Signs with Dainippon for Blonanserin

Published: 2004-12-09 06:54:00

Updated: 2004-12-09 06:54:00

Bukwang Pharmaceuticals announced the signing of a Letter of Intent (LOI) with Dainippon Pharmaceutical Co. Ltd. that provides Bukwang with exclusive licensing rights for blonanserin, an original antipsychotic agent from Dainippon, which is currently undergoing Phase 3 clinical trial in Japan.

Blonanserin is a novel antipsychotic agent, where its chemical structure differs from the existing ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.